Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer

Open access
Grisham, Rachel N., Iyer, Gopa, Garg, Karuna, DeLair, Deborah, Hyman, David M., Zhou, Qin, Iasonos, Alexia, Berger, Michael F., Dao, Fanny, Spriggs, David R., Levine, Douglas A., Aghajanian, Carol, Solit, David B. · 2013 · Cancer

Abstract

BACKGROUND: Low‐grade serous (LGS) ovarian cancer is a chemoresistant disease that accounts for 10% of serous ovarian cancers. Prior studies have reported that 28% to 35% of serous borderline (SB)/LGS ovarian tumors harbor a BRAF mutation, suggesting that BRAF inhibitors may be a rational therapeutic approach for this disease. In the current study, the authors sought to determine whether BRAF or KRAS mutation status was associated with disease stage and/or histology in patients with SB and LGS ovarian cancer. METHODS: Genetic profiles were constructed for 75 SB and LGS ovarian tumors to determine BRAF and KRAS mutation status. The incidence and identity of BRAF and KRAS mutations were defined, and the results were correlated with disease stage, response to treatment, and overall survival. RESULTS: Of 75 samples examined, 56 tumors (75%) had SB histology, and 19 tumors (25%) had LGS histology. Fifty‐seven percent of tumors harbored either a KRAS mutation (n = 17) or a BRAF mutation (a valine‐to‐glutamate substitution at residue 600 [V600E]; n = 26). The BRAF V600E mutation was associated significantly with early disease stage (stage I/II; P < .001) and SB histology (P = .002). KRAS mutations were not associated significantly with disease stage or histology. Of the 22 patients (29%) who required chemotherapy, 20 had tumors with wild‐type KRAS/BRAF, 2 had KRAS mutant tumors, and none had tumors that harbored a BRAF mutation. All patients with BRAF tumors remained alive at a median follow‐up of 3.6 years (range, 1.9–129.3 months). CONCLUSIONS: V600E BRAF mutations were present in 35% of patients who had SB/LGS ovarian cancers. The presence of the BRAF V600E mutation in SB/LGS ovarian cancer was associated with early stage disease and improved prognosis. The authors concluded that patients with SB/LGS ovarian cancer who require systemic therapy are unlikely to have BRAF mutant tumors. Cancer 2013. © 2012 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.27782

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 221

Metadata

Authors
Grisham, R. N., Iyer, G., Garg, K., DeLair, D., Hyman, D. M., Zhou, Q., Iasonos, A., Berger, M. F., Dao, F., Spriggs, D. R., Levine, D. A., Aghajanian, C., & Solit, D. B.
Venue
Cancer
Publisher
Wiley
Published
2012-08-28
Volume
119
Issue
3
Pages
548-554
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1825430271
Cited by
221
References
4
FWCI
15.37
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer. https://app.cochat.ai/papers/10.1002/cncr.27782
The paper
Grisham, R. N., Iyer, G., Garg, K., DeLair, D., Hyman, D. M., Zhou, Q., Iasonos, A., Berger, M. F., Dao, F., Spriggs, D. R., Levine, D. A., Aghajanian, C., & Solit, D. B. (2013). BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer. Cancer. https://doi.org/10.1002/cncr.27782

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.